Question & Answer

Question

Among adults with unicameral leadless pacemakers (LPs) within 90 days of reaching RRT/EOS, how does percent-predicted 6-minute walk distance (%-pred 6MWD) change from each patient’s stable baseline, and is a ≥10% decline associated with presyncope/syncope, documented backup/safety mode entry, or urgent generator replacement within 30 days?

Answer (Study-Ready Plan & Interpretation Guide)

TL;DR

Track each patient’s percent-predicted 6MWD (6MWD as % of a pre-specified normative prediction) at a stable baseline and again within 90 days of RRT/EOS. Define the primary exposure as the relative change in %-pred 6MWD. Analyze whether a ≥10% decline is associated with a composite of presyncope/syncope, entry into backup/safety mode, or urgent generator replacement within 30 days of the test. Use adjusted logistic regression (and time-to-event sensitivity analyses). A ≥10% drop that remains significant after adjustment suggests %-pred 6MWD is a practical, patient-centered marker of decompensation as battery nears end-of-service.

1) Population & Timing

Inclusion: Adults with unicameral LPs (e.g., RV device), tested within 90 days of first RRT/EOS notification.
Baseline: The most recent stable 6MWT obtained 3–12 months prior to RRT/EOS during usual clinical stability with unchanged rate-response programming.
Index test: 6MWT performed after RRT/EOS notification (or within 90 days before expected EOS, per device estimates).

2) Key Definitions

%-Predicted 6MWD

Compute predicted distance using a single pre-specified normative equation (e.g., Enright–Sherrill or a local reference). Then:

%pred_6MWD = (Observed_6MWD / Predicted_6MWD) × 100%

Use the same prediction equation for both baseline and index tests to avoid bias.

≥10% Decline

Primary binary exposure: Decline ≥10% from baseline in %-pred 6MWD at the RRT/EOS test.

Rationale: percent-based thresholds are robust across body size and commonly used when MCID in meters varies by population.

Composite Outcome (30 days)

Documented presyncope/syncope attributed to bradycardia or device behavior
Device backup/safety mode entry recorded by interrogation
Urgent generator replacement (implant) performed

3) Data to Collect (same-day preferred)

6MWT details: distance (m), perceived exertion (Borg), nadir SpO₂, HR dynamics (resting, peak, 1- & 3-min recovery), test interruptions.
Device metrics: capture threshold (V@ms), sensing amplitude (mV), impedance (Ω), lower rate limit, rate-response sensitivity/slope, any non-capture or backup mode events near test.
Clinical covariates: age, sex, BMI, hemoglobin, eGFR, LVEF, pulmonary function, β-blocker dose, orthostatic BP, comorbidities.

4) Analysis Plan

Primary comparison: Change in %-pred 6MWD from baseline to RRT/EOS test.
Model 1 (logistic): Dependent variable is the composite outcome within 30 days (yes/no). Key predictor: Decline ≥10% (yes/no). Adjust for prespecified covariates (age, sex, BMI, hemoglobin, eGFR, LVEF, β-blocker, capture threshold, lower rate limit, rate-response settings).
Model 2 (dose–response): %-pred change as a continuous variable (per 5% decrement) to estimate trend.
Sensitivity: (a) Exclude tests performed <7 days from replacement; (b) use time-to-event (Cox) with outcome date as event time; (c) replace %-based cut-off with absolute meters MCID.
Exploratory mediation: Add HR reserve/chronotropic index to see if they attenuate the %-pred effect (possible chronotropic limitation near EOS).

5) Interpreting Results

Signal present: A decline ≥10% has an adjusted OR >1 with CI excluding 1, and model fit improves (e.g., ΔAUC, NRI). Consider %-pred 6MWD as a trigger for expedited replacement evaluation.
No signal: Non-significant association after adjustment suggests %-pred 6MWD alone is insufficient; integrate device thresholds, symptoms, and rate-response diagnostics.
Heterogeneity: Effect stronger in patients with higher capture thresholds or blunted HR reserve → consider subgroup-informed programming or earlier replacement.

6) Practical Protocol (Clinic-Ready)

Select and document a single reference equation for predicted 6MWD; compute baseline %-pred now (during stability).
At RRT/EOS: repeat standardized 6MWT; export HR and SpO₂ traces if available.
Compute %-pred change; if ≥10% decline and/or presyncope, schedule urgent device review and assess for replacement readiness.
Record device interrogation (thresholds, rate-response, any safety mode flags) on the same day.

7) Reporting Template

Baseline %-pred 6MWD: ____ % (date: ____; ref eqn: ____)
RRT/EOS %-pred 6MWD: ____ % (date: ____; days from RRT: ____)
Change: ____ % (decline ≥10%? yes/no)

Composite outcome in 30 days: presyncope/syncope (y/n); backup mode (y/n); urgent replacement (y/n)
Device at test: capture ____ V@____ ms; LR limit ____ bpm; RR slope ____; sensing ____ mV; impedance ____ Ω
Key meds/covariates: ____

8) Caveats

Choose one normative equation pre hoc; switching equations between visits can fabricate changes.
Standardize corridors, encouragement, and rest rules; protocol drift inflates noise.
Address reversible factors (iron deficiency, beta-blocker up-titration, intercurrent illness) that can mimic EOS effects.

Prepared for clinical research/quality improvement; adapt to local policies and device vendor guidance.